The topic of drug prices in the United States is a conversation of ever-growing frequency and intense debate. Compounded with healthcare reform legislation and high-deductible plans, it is an issue of high importance to all Americans. Although there are mountains of data regarding this topic, a study by Express Scripts summarizes the top 15 of therapy classes in an easy-to-follow format. Express Scripts recently released its 2016 Drug Trend Report based on pharmacy claims from 30 million members of Express Scripts. The report shows a 3.8% increase in drug spending and an 11% increase in list prices of brand drugs. Here is a snapshot of their top 10 therapy classes, ranked by per-member-per-year (PMPY) spend (dollar amounts rounded):
- Inflammatory Conditions. With a PMPY spend of $118 and an average cost per prescription of $3,588, this class topped the chart. These drugs are used to treat conditions such as arthritis, psoriasis, and Crohn’s disease. The report states that this PMPY spend trend will continue at 30% year over year through 2019 and also noted that over 41% of patients are nonadherent.
- Diabetes. This class demonstrated a PMPY spend of $109 and an average cost per prescription of $126. The report states that this PMPY spend trend will continue at 20% year over year through 2019 and also noted that over 37% of patients are nonadherent.
- Oncology. This class demonstrated a PMPY spend of $61 and an average cost per prescription of $7,891. The report states that this PMPY spend trend will continue at 20% year over year through 2019 and also noted that over 35% of patients are nonadherent.
- Multiple Sclerosis. This class demonstrated a PMPY spend of $59 and an average cost per prescription of $5,056. The report states that this PMPY spend trend will continue at 10% year over year through 2019 and also noted that over 24% of patients are nonadherent.
- Pain / Inflammation. This class demonstrated a PMPY spend of $52 and an average cost per prescription of $49. The report states that this PMPY spend trend will continue at 3% year over year through 2019. These medications include opioids and nonsteroidal anti-inflammatory drugs, and this class is prolific with generics and has a 95% generic fill rate.
- HIV. This class demonstrated a PMPY spend of $40 and an average cost per prescription of $1,556. The report states that this PMPY spend trend will continue at 20% year over year through 2019 and also noted that over 24% of patients are nonadherent.
- High Blood Cholesterol. This class demonstrated a PMPY spend of $38 and an average cost per prescription of $36. The report states that this PMPY spend trend will decrease steadily year over year through 2019 and also noted that over 36% of patients are nonadherent.
- Attention Disorders. This class demonstrated a PMPY spend of $36 and an average cost per prescription of $145. The report states that this PMPY spend trend will continue at 3% year over year through 2019 and also noted that this class is dominated by generics with a 74% generic fill rate.
- High Blood Pressure / Heart Disease. This class demonstrated a PMPY spend of $35 and an average cost per prescription of $14. The report states that this PMPY spend trend will decrease steadily year over year through 2019 and also noted that over 28% of patients are nonadherent.
- Asthma. This class demonstrated a PMPY spend of $30 and an average cost per prescription of $69. The report states that this PMPY spend trend will eventually decline by 2019 due to oncoming generics and also noted that over 73% of patients are nonadherent.
The next five therapy classes shown in the report are: Hepatitis C (#11), Depression (#12), Contraceptives (#13), Heartburn / Ulcer Disease (#14), and Skin Conditions (#15). The 2016 Drug Trend Report can be found here.
==============================================================
Contact ABISA for healthcare consultancy support or speaking engagements. Follow on Twitter @ABISALLC